Product
Abiraterone acetate plus prednisone
1 clinical trial
1 indication
Clinical trial
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2025-06-30